Refractory sickle cell leg ulcer: is heparan sulphate a new hope?

Shady Hayek¹, Saad Dibo¹, Joe Baroud¹, Amir Ibrahim¹ & Denis Barritault²

¹ Plastic and Reconstructive Surgery, Private Practice, American University of Beirut – Medical Center, Beirut, Lebanon
² Laboratoire CRRET CNRS, University Paris Est Creteil, Paris, France

Key words
Cacipliq®; Glucose amino glycans; Heparan sulphate; Sickle cell ulcer; Ulcer

Correspondence to
S Hayek, MD
Assistant Professor of Surgery
Plastic and Reconstructive Surgery
Private Practice
Beirut
Lebanon
E-mail: hayek010@umn.edu

Abstract
Patients with sickle cell disease are known to have recurrent lower extremity ulcers that have a high pain score and are resistant to conventional means of wound therapy. This study reports the successful use of synthetic heparan sulphate (Cacipliq® (OTR3, Paris, France)) in the treatment of a sickle cell ulcer that had failed to respond to several other means of treatment. Therapeutic success was assessed by complete wound coverage and vast improvement in pain score. This is the first study to report use of heparan sulphate in sickle cell ulcers.

Introduction
Sickle cell disease (SCD) is caused by the production of an abnormal sickle shaped haemoglobin that is moderated by the persistence of foetal haemoglobin (1). The polymerisation of this abnormal haemoglobin results in clumping and obstruction of small vessels leading to ischaemic changes especially in areas with poor or limited blood supply such as the ankles and the anterior tibial areas (1–3). This results in recurrent skin ulcers that are sometimes resistant to conventional wound management modalities (1–3). It is estimated that skin ulcers occur in 25–75% of patients with SCD (1–12). Historically the treatment consists of transfusions, local wound care and skin grafting with a high recurrence rate and long hospital stays (1,7).

In this article we report a case of recurrent sickle cell ulcer refractory to all conservative and surgical measures in a 25-year-old woman, who was successfully treated by repeated topical application of a newly developed heparan sulphate solution marketed as Cacipliq® (OTR3, Paris, France).

Case description
The patient was a 25-year-old woman who was referred by her haematologist in 2005 for a non-healing sickle cell ulcer over the lateral aspect of her left ankle. Her haemoglobin analysis showed a pattern compatible with homozygous SCD also known as sickle β-thalassemia (Table 1). At that time she was treated with Promogran® (Johnson & Johnson Medical, Skipton, UK), and the ulcer healed over a few weeks time.

She was doing fine on regular follow ups until she came back in November of 2008 with recurrence of the same ulcer. Her pain level was estimated to be 10 on the visual analogue scale (VAS). The wound was dry and showed no signs of infection. She was started on moist wound therapy to no avail, followed by Promogran® (Johnson & Johnson) for 8 weeks without any improvement. In December of 2009 she underwent tangential excision of the ulcer bed followed by full thickness skin graft application a few days later when the bed had showed good granulation tissue growth. After a 2-week period of unremarkable postoperative course, a small ulcer started to appear at the edge, enlarging over a short time to cover the whole original wound size. The wound was treated conservatively and the patient received several transfusions that helped slow the growth of the ulcer, failing to revert it into

Key Messages
• this is the first case report of using heparan sulphate to treat a chronic and difficult-to-heal ulcer secondary to a sickle cell disease
• it aims at shedding the light on this possible new treatment modality that seems encouraging in this difficult pathology
• despite the fact that this is a single-case report, it would be of benefit to look at the experience of other physicians in this field and especially their experience in using heparan sulphate for such difficult wounds
Refractory sickle cell leg ulcer: is heparan sulphate a new hope?

S. Hayek et al.

Table 1  Haemoglobin fractions

<table>
<thead>
<tr>
<th>Haemoglobin fractions</th>
<th>Result</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbF</td>
<td>17.1%</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td>HbA2</td>
<td>4.6%</td>
<td>1.5–3.2</td>
</tr>
<tr>
<td>HbA</td>
<td>2.5%</td>
<td></td>
</tr>
<tr>
<td>HbS</td>
<td>74.0%</td>
<td></td>
</tr>
<tr>
<td>HbC</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>HbD</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Hb pattern</td>
<td>SS*</td>
<td></td>
</tr>
</tbody>
</table>

*Compatible with sickle cell disease

Figure 1  The patient’s ulcer before the first application of Cacipliq20®.

a healing wound. Vacuum assisted closure device attenuated the pain to a level of 7 on the VAS but the wound remained resistant to closure. An unsuccessful trial of mist therapy accompanied by an exchange transfusion was also attempted by another Physician. The availability of topical heparan sulphate (Cacipliq20®, OTR3) as an alternative treatment option was discussed with the patient. She was informed that it had not yet been tried on sickle cell ulcers, but that there was some promising evidence in arterial ischaemic ulcers. The patient agreed to use it (Figure 1 showing the ulcer location and size before application of Cacipliq20®). The treatment consisted of topical application of the heparan sulphate solution to the wound twice weekly for 5 minutes each time, alternating with a normal saline moist dressing changed on daily basis. The pain level decreased to 2–3 on the VAS over the second week and to 0 thereafter. The wound gradually improved (Figure 2) after that and it healed completely over a total period of 8 weeks of application of topical heparan sulphate (Figure 3). The patient was followed up in the clinic for a period of 12 months and the wound remained covered with a stable tissue (Figure 4) coupled with a level 0 pain on the VAS.

Discussion

Glycosaminoglycans (GAGs) are usually divided into two groups (8,9):

1. Intracellular or membrane associated such as syndecans and glypicans

2. Extracellular such as perlecan and agrin

The different types of GAGs are classified according to the amount of sulphation and the size of the oligosaccharide attached to them (8,9). These molecules have been found to be crucial for several cellular and intercellular processes including inflammation (10–12), neurodegeneration (13), angiogenesis (14), cardiovascular diseases (15), cancer (16) and infectious diseases (17–19). Heparin and heparan sulphate are GAGs that have 1–4 linked uronic acid and glycosamine with varying amounts of sulphation allowing them to be involved in several activities including binding to anti-thrombin producing the anticoagulant activity of Heparin (9,20). Recently, the therapeutic value of heparin and heparan sulphate in wound healing has been more appreciated because of their ability to bind, activate and immobilise a variety of growth factors, chemokines and metalloproteinases (21,22). A molecule called OTR4120, structurally similar to heparin but ten times less potent as an anticoagulant (23), has been shown to enhance wound healing in animal models for peripheral nerve injury (24), burn skin (25), chronic ulcers (26) and cutaneous wound
repair in rats (27). One of the approaches to treat chronic non-healing wounds is to replace the GAGs in the extracellular matrix in order to restore tissue homeostasis and to protect the wound from further damage (28). Cacipliq® is a skin specific synthetic bioengineered heparan sulphate GAG mimetic which replaces the heparan sulphate that was destroyed in the wound, restoring the extracellular matrix scaffold and allowing key interactions with growth factors to occur (28). Moreover, synthetic heparan sulphate mimetic is resistant to destruction by endoglycosidase, making it efficient in restoring the extracellular matrix by binding to heparan-binding sites that become available when the endogenous heparan sulphate is destroyed by heparanase activation (28–30).

Earlier studies have shown that this heparan sulphate mimetic promotes wound healing both in vivo and in vitro (28). In vitro, it has been shown to enhance angiogenesis by modulating vascular endothelial growth factor (VEGF) and collagen-type expression via fibroblast growth factor 2 (FGF-2) and transforming growth factor β1 (TGF-β1) (31–34). In vivo, this molecule was able to induce angiogenesis in ischaemic, cardiac and skeletal muscles (31,32), and to improve wound healing, decrease inflammation and improve wound quality in mice with skin ulcers (34,35). Such effects were observed in several wound types including drug-induced skin ulcers, burn wounds, irradiation-induced wounds, post-surgery wounds and pressure-induced wounds (25,27,36,37). In 2008, Barritault et al. presented during the second World Union of Wound Healing Societies meeting in Toronto their first results on humans treated with Cacipliq® (38). In this pilot study they studied 15 chronic arterial ulcers to which they applied Cacipliq®. They reported that at 1 month post application 80% of the ulcers improved and the size reduction was reported to be between 12% and 100% with good tolerance and reduced pain. Of the three patients (20%) who did not benefit from the medication, two died and the third underwent amputation (38). In 2011, Suzan Groah from Washington DC reported on a similar study carried out in an underserved metropolitan area on patients with chronic ulcers ranging in duration between 2-5 and 10 years (28). The researchers in this study were able to show that 22% of the participants had complete healing in 1 month (28). Seven patients in this study had pressure ulcers and spinal cord paralysis representing a high-risk group and indicating the level of recalcitrant wounds that were being treated in the study (28). Despite all these factors the researchers were able to show that at least for the first three sessions, the decrease in the wound size was close to the normal rate for healthy acute wounds (28).

Another important setback in chronic wounds in general and sickle cell ulcers in specific is pain. Groah et al. reported in their study that the pain level decreased profoundly as measured by two different tools (28). In our patient, the same decrease in pain level was noted from the first session of application. This decrease in pain was even noticed before any clinically visual changes in the wound size were even noted. The authors propose that this decrease in pain might represent a decrease in the level of inflammatory components of the wound, a theory yet waiting to be proven.

To our knowledge, this is the first case study using Cacipliq® for treating sickle cell ulcers. Several treatment options for these ulcers exist in the literature. Nevertheless, they all share a high rate of recurrence and are associated with high failure rates (1,7). Treatment with Cacipliq® might set a new horizon, but are yet to be studied in future randomised prospective trials.

References

17. Rostand KS, Esko JD. Microbial adherence to and invasion through
22. Volpi N. Therapeutic applications of glycosaminoglycans.
24. Zuijdendorp HM, Smit X, Blok JH, Caruelle JP, Barritault D,
26. Barbier-Chassefi`ere V, Garcia-Filipe S, Yue XL, Kerros ME, Petit E,
27. Tong M, Tuk B, Hekking IM, Vermeij M, Barritault D, van Neck
15. Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L. Hep-
19. Wadstrom T, Ljungh A. Glycosaminoglycan-binding microbial pro-
21. Gesslbauer B, Kungl AJ. Glycomic approaches toward drug devel-
13. D ´ıaz-Nido J, Wandosell F, Avila J. Glycosaminoglycans and b-